KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Total Debt (2019 - 2025)

Historic Total Debt for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to $8.9 billion.

  • Royalty Pharma's Total Debt rose 1759.29% to $8.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $8.9 billion, marking a year-over-year increase of 1759.29%. This contributed to the annual value of $7.6 billion for FY2024, which is 2407.62% up from last year.
  • As of Q3 2025, Royalty Pharma's Total Debt stood at $8.9 billion, which was up 1759.29% from $8.0 billion recorded in Q2 2025.
  • Royalty Pharma's Total Debt's 5-year high stood at $8.9 billion during Q3 2025, with a 5-year trough of $5.9 billion in Q1 2021.
  • In the last 5 years, Royalty Pharma's Total Debt had a median value of $7.2 billion in 2021 and averaged $7.1 billion.
  • Over the last 5 years, Royalty Pharma's Total Debt had its largest YoY gain of 2407.66% in 2024, and its largest YoY loss of 1378.96% in 2024.
  • Quarter analysis of 5 years shows Royalty Pharma's Total Debt stood at $7.2 billion in 2021, then fell by 1.22% to $7.1 billion in 2022, then fell by 13.79% to $6.1 billion in 2023, then rose by 24.08% to $7.6 billion in 2024, then rose by 17.51% to $8.9 billion in 2025.
  • Its Total Debt was $8.9 billion in Q3 2025, compared to $8.0 billion in Q2 2025 and $7.6 billion in Q1 2025.